CCXI
Churchill Capital Corp XI Class A Ordinary SharesNASDAQFINANCIAL SERVICESSHELL COMPANIES
Key Statistics
Market Cap
$3.74B
P/E Ratio
—
EPS
$-2.00
Beta
1.23
52W High
$0.00
52W Low
$0.00
50-Day MA
$51.50
200-Day MA
$31.84
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Churchill Capital Corp XI Class A Ordinary Shares
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.
Fundamentals
| Revenue (TTM) | $37.28M |
| Gross Profit (TTM) | $-51.07M |
| EBITDA | $-127.60M |
| Operating Margin | -353.20% |
| Return on Equity | -47.00% |
| Return on Assets | -18.50% |
| Revenue/Share (TTM) | $0.53 |
| Book Value | $3.31 |
| Price-to-Book | 15.81 |
| Price-to-Sales (TTM) | 100.30 |
| EV/Revenue | 93.62 |
| EV/EBITDA | -27.52 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 549.00% |
| Shares Outstanding | $71.92M |
| Float | $58.98M |
| % Insiders | 12.01% |
| % Institutions | 84.39% |
More FINANCIAL SERVICES Stocks
Data last updated: 5/2/2026